REG - Cambridge Cognition - Launch of Speaker Identification Solution

Cambridge Cognition HoldingsAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250812:nRSL8702Ua&default-theme=true

RNS Number : 8702U  Cambridge Cognition Holdings PLC  12 August 2025

12 August 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition launches Speaker Identification Solution to Safeguard
Clinical Trial Integrity

 

Cambridge Cognition Holdings plc (AIM:COG), the brain health software group
specialising in digital health products that advance brain health research and
treatment, is pleased to announce the commercial launch of a proprietary
speaker identification solution developed to tackle duplicate participant
enrolment in clinical trials. This development continues to build on the
Company's suite of AI voice enabled data quality management tools. The
solution has already secured initial commercial deals and is scheduled to be
deployed by a large pharmaceutical customer in Q4 2025.

 

Duplicate enrolment, where participants enrol in multiple concurrent trials,
presents a growing challenge in clinical research, affecting data integrity,
study validity and cost efficiency. Published data reports that up to 22% of
participants may engage in overlapping trials(1).

 

Developed on Cambridge Cognition's proven AI-enabled voice technology
platform, the solution compares recorded voice samples collected during trial
visits with a database of enrolled participants and addresses the risk of
duplicate enrolments by using advanced voice biometrics to verify
participants' identity across trial enrolment databases. The system operates
during the screening phase to flag potential duplicates before data
contamination occurs, ensuring reliable and non-duplicated data collection.
The solution is GDPR and HIPAA compliant, scalable across languages, with
potential application to a wide range of therapeutic areas, and has
demonstrated over 97% accuracy². The Company believes there is significant
demand for this solution and strong prospects for adoption wherever
participant verification and cognitive data integrity are critical.

 

This launch further strengthens the Group's growing suite of quality assurance
tools, including the Automated Quality Assurance (AQUA) offering and reflects
the Company's strategic commitment to enhancing reliability and efficiency for
pharmaceutical and biotech companies conducting clinical research.

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

 "With our new speaker identification solution, sponsors can proactively
address one of the most under-recognised risks in clinical trials, duplicate
enrolments. This launch demonstrates the power, flexibility and growing
commercial potential of our leading voice analytics platform and underscores
our commitment to data quality in global clinical research."

1.     Lee, C. P., Holmes, T., Neri, E., & Kushida, C. A. (2018).
Deception in clinical trials and its impact on recruitment and adherence of
study participants. Contemporary clinical trials, 72, 146-157.
https://doi.org/10.1016/j.cct.2018.08.002
(https://doi.org/10.1016/j.cct.2018.08.002)

2.     Akram, A., Stanojevic, M., Ehghaghi, M., & Novikova, J. (2024).
Zero-shot multi-lingual speaker verification in clinical trials. arXiv
preprint arXiv:2404.01981.

 

 

Enquiries

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / Amber Higgs

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Jackson Redley                  cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·     Consumer Health & Wellness provides individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

 

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPBMFTMTBBBTA